Welcome to our dedicated page for Palatin Tech news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Tech stock.
Palatin Technologies develops biopharmaceutical product candidates based on molecules that modulate the melanocortin receptor system. Company news centers on its melanocortin-based obesity programs, including oral small-molecule and peptide MC4R agonists, with focus areas that include hypothalamic obesity and Prader-Willi syndrome.
Recurring updates also cover ocular and retinal disease assets, including PL9643 for dry eye disease and PL9654 and PL9655 for diabetic retinopathy, along with research collaborations, sublicensing agreements, public offerings, reverse-stock-split actions, exchange trading status and financial results.
Palatin Technologies, Inc. (NYSE American: PTN) announced its participation in the H.C. Wainwright BioConnect Virtual Conference from January 10–13, 2022. CEO Carl Spana, PhD, will discuss the company's pipeline and provide an update on the Phase 3 MELODY-1 study of PL9643 for dry eye disease. The presentation will be available for on-demand listening starting January 10 at 7:00 a.m. ET. Interested parties can request one-on-one meetings by contacting their H.C. Wainwright representatives or emailing ir@palatin.com.
Palatin Technologies (NYSE American: PTN) has commenced the pivotal Phase 3 MELODY-1 clinical study for PL9643, targeting dry eye disease. This multi-center study will enroll up to 400 patients across the U.S., with top-line results expected in the second half of 2022. Following positive Phase 2 results, Palatin has coordinated with the FDA on study design and key elements necessary for potential New Drug Application (NDA) filings. The Phase 3 program is categorized as a significant milestone for both the company and patients.
Palatin Technologies, Inc. (NYSE American: PTN) announced a Notice of Allowance from the U.S. Patent and Trademark Office for application No. 16/927,347. This patent pertains to the use of melanocortin peptides for reducing pro-inflammatory cytokine levels associated with cytokine storms, a condition linked to immune system dysregulation. CEO Carl Spana highlighted the significance of strengthening their intellectual property surrounding this technology, particularly given its potential implications for diseases like COVID-19. The patent broadens Palatin's portfolio of melanocortin receptor-1 peptides aimed at tackling inflammation.
Palatin Technologies (PTN) reported its fiscal Q1 2022 results, highlighting significant advances in its melanocortin agonist programs. The company expects to initiate a Phase 3 study for PL9643 in December 2021 and a Phase 2 trial for PL8177 in early 2022. Vyleesi's net revenue surged 98% quarter-over-quarter, reaching $159,482, despite a 13% drop in total prescriptions. Total operating expenses rose to $7.4 million, up from $3.7 million in the prior year. Palatin's cash position stands at $53.4 million, sufficient to cover anticipated expenses through 2022.
Palatin Technologies (NYSE American: PTN) will announce its Q1 FY 2022 operating results on November 15, 2021, before U.S. market opening. A conference call will follow at 9:30 a.m. ET, including a review of results and updates on development programs. The results press release will be issued at 7:30 a.m. ET, with a replay available until November 22, 2021. Interested parties can access the audio webcast through Palatin's website.
Summary not available.
Palatin Technologies, Inc. (PTN) reported its fourth quarter and fiscal year results, highlighting a successful Phase 2 trial for PL9643, aimed at treating dry eye disease. The company has a cash position of $60.1 million, expected to support operations through 2022. PL9643’s/b pivotal Phase 3 trial is set for Q4 2021, with results anticipated in H2 2022. Quarterly gross product sales of Vyleesi reached $1.2 million, marking a 28% rise, yet quarterly net revenue showed a decline of 9%. Palatin’s net loss was $13.9 million, resulting in an EPS of $0.06.
Palatin Technologies, Inc. (PTN) announced promising results on melanocortin agonists PL8331 and PL9654 at the 2021 ASRS Annual Meeting. The data showcases protective effects against retinal inflammation in mouse models, highlighting potential treatments for diabetic retinopathy. CEO Carl Spana emphasized ongoing positive results in inflammatory disease models. The presentation, scheduled for October 9, 2021, will feature these findings, reinforcing the company's focus on the melanocortin system's therapeutic applications.
Palatin Technologies, Inc. (PTN) will announce its Q4 and fiscal year end 2021 operating results on September 29, 2021, prior to the market opening. A conference call will follow at 11:00 a.m. ET, providing a review of the operating results and updates on ongoing programs. Investors can access the audio webcast through Palatin's website. This announcement is pivotal as it provides insight into the company's financial performance and strategic direction for potential investors.
Palatin Technologies (NYSE American: PTN) announced its participation at the TIDES USA hybrid conference in Boston from September 20-23, 2021. The company will feature a presentation and two poster presentations focused on its melanocortin peptide research, targeting inflammation. CEO Carl Spana will discuss the development of melanocortin-based therapeutics, while John Dodd will present data on colon inflammation. The presentations aim to showcase potential treatments in inflammatory conditions.